Search company, investor...
HiFiBiO Therapeutics company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Series D | Alive

Total Raised


Last Raised

$75M | 1 yr ago

Mosaic Score

+20 points in the past 30 days

What is a Mosaic Score?
The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.

About HiFiBiO Therapeutics

HiFiBiO Therapeutics is a multinational biotherapeutics company mobilizing the human immune system to combat disease. The company integrates biological expertise with its single-cell profiling technologies to discover and advance a pipeline of antibody drugs to treat cancer and autoimmune disorders.

HiFiBiO Therapeutics Headquarters Location

29 Rue du Faubourg Saint-Jacques

Paris, 75014,


ESPs containing HiFiBiO Therapeutics

The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.

Life Sciences / Biopharma Tech

These companies provide laboratory equipment and software to sequence, observe, and analyze individual cells. Solutions in this space enable pharma companies to develop therapies based on rare cellular genetics and phenotypes.

HiFiBiO Therapeutics named as Leader among 15 other companies, including Mission Bio, Celsius Therapeutics, and immunai.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing HiFiBiO Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

HiFiBiO Therapeutics is included in 3 Expert Collections, including Biopharma Tech.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.



3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.


Drug Discovery Tech Market Map

221 items

This CB Insights Tech Market Map highlights 220 drug discovery companies that are addressing 12 distinct technology priorities that pharmaceutical companies face.

HiFiBiO Therapeutics Patents

HiFiBiO Therapeutics has filed 1 patent.

The 3 most popular patent topics include:

  • Epigenetics
  • Experimental cancer drugs
  • MicroRNA
patents chart

Application Date

Grant Date


Related Topics



MicroRNA, Epigenetics, Experimental cancer drugs, Monoclonal antibodies, Molecular biology


Application Date


Grant Date


Related Topics

MicroRNA, Epigenetics, Experimental cancer drugs, Monoclonal antibodies, Molecular biology



Latest HiFiBiO Therapeutics News

HiFiBiO Therapeutics Announces Clinical Trial Supply Agreement to Evaluate HFB200301 in Combination with Tislelizumab in Patients with DIS™ Selected Advanced Solid Tumors

Aug 15, 2022

August 15, 2022 08:03 AM Eastern Daylight Time CAMBRIDGE, Mass.--( BUSINESS WIRE )--HiFiBiO Therapeutics, a multinational clinical-stage biotherapeutics company, announced today a clinical trial supply agreement with Novartis to evaluate tislelizumab, an anti-PD-1 immune checkpoint inhibitor, in combination with HiFiBiO’s HFB200301, an investigational first-in-class monoclonal anti-TNFR2 agonist antibody for the potential treatment of advanced solid tumor indications preselected by HiFiBiO’s proprietary Drug Intelligence Science (DIS™) platform. HFB200301 is currently being evaluated as a single agent in the first-in-human dose escalation and expansion clinical trial ( NCT05238883 ), with the intention of following up with a combination of HFB200301 and tislelizumab. “Immuno-oncology therapies have significantly improved the way we treat cancers. Unfortunately, they are not effective in every patient, and many individuals are still left with few options. Combination immunotherapy approaches have become a promising solution for harder to treat cancers,” said Luigi Manenti, M.D., Chief Medical Officer at HiFiBiO Therapeutics. “HFB200301 has the potential to reenergize the immune system to fight against cancers, both as a single agent and in combination. We are excited to explore whether HFB200301 in combination with tislelizumab can further improve patient outcomes in DIS™ selected cancers.” “HiFiBiO is proud to highlight the potential of our DIS™ platform to rapidly advance novel therapeutics like HFB200301 from targets to patients. Additionally, this collaboration showcases our continuing commitment to Open Innovation for the benefit of cancer patients with high unmet needs,” said Liang Schweizer, Ph.D., Founder, Chairperson and CEO at HiFiBiO Therapeutics. Under the terms of the agreement, HiFiBiO Therapeutics will maintain control of the HFB200301 program, including global R&D and commercial rights. Novartis has agreed to supply tislelizumab for use in combination with HFB200301. HFB200301 HFB200301 is a first-in-class agonistic anti-TNFR2 antibody that binds potently and selectively to TNFR2 and induces the activation of CD4 T cells, CD8 T cells and NK cells. In vivo, HFB200301 demonstrates potent antitumor activity as a single agent and in combination with anti-PD-1. HiFiBiO is applying a biomarker strategy by leveraging its DIS™ platform to select indications that may benefit the most from HFB200301 treatment. HFB200301 is an investigational agent. Safety and efficacy have not been established. There is no guarantee that HFB200301 will become approved and commercially available anywhere globally. Tislelizumab Tislelizumab is a humanized IgG4 anti-PD-1 monoclonal antibody specifically designed to minimize binding to Fc-gamma (Fcγ) receptors on macrophages. In pre-clinical studies, binding to Fcγ receptors on macrophages has been shown to compromise the anti-tumor activity of PD-1 antibodies through activation of antibody-dependent macrophage-mediated killing of T effector cells. About HiFiBiO Therapeutics HiFiBiO Therapeutics is a clinical stage biotech company advancing a robust pipeline targeting both the innate and adaptive immunity to treat cancer and autoimmune diseases. Its proprietary and versatile DIS™ single-cell platform enables the rapid discovery of novel antibody therapeutics with predictive biomarkers through our internal development programs and strategic collaborations. Our passionate team across three continents embraces a fast-paced and engaging work environment to bring transformative medicines to patients. HiFiBiO Therapeutics, HiFiBiO Therapeutics logo, and DIS are trademarks of HiFiBiO and its affiliates. Contacts

HiFiBiO Therapeutics Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

HiFiBiO Therapeutics Rank

  • When was HiFiBiO Therapeutics founded?

    HiFiBiO Therapeutics was founded in 2013.

  • Where is HiFiBiO Therapeutics's headquarters?

    HiFiBiO Therapeutics's headquarters is located at 29 Rue du Faubourg Saint-Jacques, Paris.

  • What is HiFiBiO Therapeutics's latest funding round?

    HiFiBiO Therapeutics's latest funding round is Series D.

  • How much did HiFiBiO Therapeutics raise?

    HiFiBiO Therapeutics raised a total of $179.5M.

  • Who are the investors of HiFiBiO Therapeutics?

    Investors of HiFiBiO Therapeutics include Sequoia Capital China, IDG Capital, Further Global Capital, Hengxu Capital, Trinity Innovation Fund and 17 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.